However, some CAR-T cell therapies in clinical trials are targeting antigens that are expressed in both tumor and normal tissues (e.g. mesothelin, GD2, and IL13Rα2) and are demonstrating favorable responses without obvious adverse effects (Beatty et al., 2014; Brown et al., 2016; Rossig et al., 2002). This evidence concerns the gene MSLN and neoplasm.